Compare · ATEC vs RMD
ATEC vs RMD
Side-by-side comparison of Alphatec Holdings Inc. (ATEC) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATEC and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 20.2x ATEC ($1.69B).
- Over the past year, ATEC is down 29.7% and RMD is down 10.8% - RMD leads by 18.8 points.
- RMD has been more active in the news (9 items in the past 4 weeks vs 3 for ATEC).
- RMD has more recent analyst coverage (25 ratings vs 20 for ATEC).
- Company
- Alphatec Holdings Inc.
- ResMed Inc.
- Price
- $10.46-4.30%
- $239.08-1.35%
- Market cap
- $1.69B
- $34.07B
- 1M return
- +1.70%
- +4.60%
- 1Y return
- -29.68%
- -10.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- News (4w)
- 3
- 9
- Recent ratings
- 20
- 25
Alphatec Holdings Inc.
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is based in Carlsbad, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest ATEC
- SEC Form 4 filed by Alphatec Holdings Inc.
- New insider Carls Thomas Andrew claimed ownership of 2,520 shares (SEC Form 3)
- ATEC Appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy
- CEO Miles Patrick bought $1,013,150 worth of shares (115,000 units at $8.81), increasing direct ownership by 2% to 5,893,551 units (SEC Form 4)
- GENERAL COUNSEL & CORP. SEC. Marshall Tyson Eliot sold $78,821 worth of shares (8,168 units at $9.65) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 630,398 units (SEC Form 4) (for tax liability)
- SEC Form 10-Q filed by Alphatec Holdings Inc.
- SEC Form S-8 filed by Alphatec Holdings Inc.
- Alphatec Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ATEC Reports Second Quarter Financial Results
- UBS initiated coverage on Alphatec with a new price target
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target